Clinical Trial Update: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2b trial evaluating GC4711 in combination with SBRT for nonmetastatic pancreatic cancer was terminated, with results posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer
• Pancreatic Cancer
• Unresectable Pancreatic Cancer

Drugs mentioned

• GC4711

Snippet

Sponsor: Galera Therapeutics, Inc. | Conditions: SBRT, Borderline Resectable Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-05-21